Tandem Diabetes Care, Inc. (TNDM)
NasdaqGM
Price as at 1 Oct 2026, 12:27 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Tandem Diabetes Care, Inc. trades at $16.31. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$26.19M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$19.79M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$10.29M · 0.0% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$10.08M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$9.22M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in TNDM
We hold 6 disclosed trades in TNDM by members of Congress and executive-branch officials. The latest 5:
- Donald J Trump · Executive branchSell · $1,001 - $15,000 · traded 15 May 2026 · disclosed 1 Jul 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 3 Mar 2026 · disclosed 7 Apr 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 4 Mar 2025 · disclosed 7 Apr 2025
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 29 Jul 2024 · disclosed 22 Sept 2026
- Donald J Trump · Executive branchBuy · $15,001 - $50,000 · traded 17 Jul 2024 · disclosed 22 Sept 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own TNDM?
9 of the institutions we track reported a position in TNDM in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its TNDM data?
Fundamentals for TNDM come from company filings and exchange data, as listed on NasdaqGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 12:27 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for TNDM, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.